PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers

Phase I data represent first clinical proof-of-concept for targeting Hippo-YAP-TEAD pathway

AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers
2023-04-16
(Press-News.org) ABSTRACT: CT006

ORLANDO, Fla. ― The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center. The first-in-human study was presented today at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Seven of 69 patients had radiological partial responses that persisted up to at least 21 months, indicating tumor shrinkage, while 34 had stable disease. Patient benefit was observed in patients with both mesothelioma and other solid tumors, including those with and without NF2 mutations.

“This is the first clinical proof-of-concept for drugging the Hippo-YAP-TEAD pathway,” said presenter and lead author Timothy A. Yap, M.D., Ph.D., associate professor of Investigational Cancer Therapeutics. “We’ve long known that YAP is a key oncogenic driver of cancer, and preclinical research suggested blocking YAP could shrink tumors. However, this is the first data demonstrating that targeting YAP can work in a clinical setting to actually benefit patients.”

YAP (yes-associated protein) is a transcriptional co-activator that works with TEAD (transcriptional enhancer activator domain) as a part of the Hippo signaling pathway, which is important for normal cell growth and regulating the immune response. However, in several cancer types, YAP is either overexpressed or over-activated due to dysfunction in the pathway, fueling cancer cell growth. Therefore, YAP represents an attractive therapeutic target.

VT3989 works by inhibiting TEAD palmitoylation, which in turn blocks YAP function. NF2-mutant cancers were chosen for this trial due to their dependence on YAP activity for growth.

The Phase I dose escalation trial was designed to evaluate the safety, tolerability and recommended Phase II dose for VT3989. Today’s presentation includes data on 69 enrolled patients, including 43 with advanced malignant mesothelioma and 26 with other solid tumors. Patients were heavily pre-treated and received a median of three prior lines of therapy. A total of 37 patients had NF2 mutations. Patients in the trial were 51% male and 49% female, 87% white, 10% Hispanic and 3% Black, with a median age of 63.5. 

The drug was well tolerated, with no dose-limiting toxicities observed. The most common adverse events were albuminuria (a reversible increase in the protein albumin in the urine), swelling in the extremities, fatigue and nausea. Only seven grade 3 adverse events were possibly treatment-related, including albuminuria, swelling, fatigue, and increased liver enzymes alanine transaminase and aspartate aminotransferase, along with one possibly related grade 4 cardiomyopathy.

“These are early but very promising results showing that this previously ‘undruggable’ target and anti-cancer strategy can work in a clinical setting,” Yap said. “We look forward to future results from this study in order to evaluate whether this approach may bring an urgently needed treatment option to these patients.”

Ongoing dose optimization cohorts of the study are investigating different dosing and scheduling in two-stage designs. 

The trial was supported by Vivace Therapeutics. A complete list of collaborating authors and their disclosures can be found here.

END

[Attachments] See images for this press release:
AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers

ELSE PRESS RELEASES FROM THIS DATE:

AACR: Penn Medicine preclinical study identifies new target for recurrent ovarian cancer

2023-04-16
ORLANDO – Despite recent advances, ovarian cancer remains the fifth leading cause of cancer-related deaths among women, and there’s a critical need for new treatment options, especially for advanced cancers that grow back after standard of care treatment. Results from a preclinical study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, verified a new target for drug-resistant ovarian cancer and provided data to support a treatment approach that is already making its way into clinical trials. Sarah Gitto, PhD, an instructor of Pathology and Laboratory ...

Adding new vaccine type to leading immunotherapy dramatically reduced melanoma recurrence

2023-04-16
VIDEO OF RESEARCHER AND PATIENT COMMENTARY IS AVAILABLE AT: https://bcove.video/3mxxASq   The combination of an experimental mRNA vaccine with an immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared to immunotherapy alone, a new clinical trial shows. Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the randomized phase 2b trial involved men and women who had surgery to remove melanoma from lymph nodes or other organs and were at high risk of the disease returning in sites distant from the original cancer.            ...

AACR: Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery

AACR: Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
2023-04-16
ABSTRACT: CT005  ORLANDO, Fla. ― A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.   The ...

A new breakthrough in Alzheimer disease research - visualizing reactive astrocyte-neuron interaction

A new breakthrough in Alzheimer disease research - visualizing reactive astrocyte-neuron interaction
2023-04-16
Recently, a team of South Korean scientists led by Director C. Justin LEE of the Center for Cognition and Sociality within the Institute for Basic Science made a new discovery that can revolutionize both the diagnosis and treatment of Alzheimer’s Disease. The group demonstrated a mechanism where the astrocytes in the brain uptake elevated levels of acetates, which turns them into hazardous reactive astrocytes. They then went on further to develop a new imaging technique that takes advantage of this mechanism to directly observe the astrocyte-neuron interactions. Alzheimer’s disease (AD), one of ...

Statin use is associated with lower risk of stroke in patients with atrial fibrillation

2023-04-16
Barcelona, Spain – 16 April 2023:  A region-wide study in more than 50,000 patients with atrial fibrillation has found reduced risks of stroke and transient ischaemic attack in those who started statins within a year of diagnosis compared with those who did not. The findings are presented at EHRA 2023, a scientific congress of the European Society of Cardiology (ESC).1   “Our study indicates that taking statins for many years was even more protective against stroke than short-term use,” said study author Ms. Jiayi Huang, a PhD student at the University of Hong Kong, China.   Atrial fibrillation is the most common ...

ARRS Annual Meeting: 3D SVR MRI helps delineate fetal optic nerve pathway

ARRS Annual Meeting: 3D SVR MRI helps delineate fetal optic nerve pathway
2023-04-16
Honolulu, HI | April 16, 2023—An award-winning Scientific Online Poster presented during the 2023 ARRS Annual Meeting on the island of Oahu explained how the novel technique of three-dimensional (3D) slice-to-volume (SVR) MRI allows for precise delineation and measurement of the fetal optic pathway (FOP). Noting the limited fetal presentation and low reproducibility of ultrasound-based techniques, as well as conventional MRI’s inconsistencies in FOP visualization due to low resolution (i.e., large slice thickness), “our preliminary results nevertheless demonstrate the promises and utility of this technique,” said Eric Juang, MS, of Creighton University ...

Erik Paulson gaveled in as president of American Roentgen Ray Society (ARRS)

Erik Paulson gaveled in as president of American Roentgen Ray Society (ARRS)
2023-04-16
Honolulu, HI | April 16, 2023—Erik K. Paulson, MD, chair of the radiology department at Duke University, has been named the 123rd President of the American Roentgen Ray Society (ARRS) during the opening ceremony of the 2023 ARRS Annual Meeting in Honolulu, HI. “I am absolutely honored and delighted to serve as the President of our country’s oldest radiology society, a society whose sweet spot is member education,” Dr. Paulson said in his ARRS Annual Meeting opening remarks at ...

UK strep A research shows highest incidence of invasive disease has shifted from the most deprived groups to the second most affluent group

2023-04-16
  **Note: the release below is from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April). Please credit the conference if you use this story** Measures introduced to reduce transmission of COVID-19 infections during 2020-2021 suppressed transmission of group A streptococcal (GAS) infections, particularly in children. Following the lifting of public health restrictions in the UK in Feb-2022, Group A Streptococcus presentations – including scarlet fever and invasive Group A Strep – rose significantly in England, although iGAS still remained very ...

Surge of strep A infections, including more dangerous invasive type, has affected Denmark since late 2022, especially in the elderly

2023-04-16
**Note: the release below is from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April). Please credit the conference if you use this story** During the 2022-2023 winter season Denmark experienced a surge in infections caused by group A streptococci (GAS), including the more dangerous, invasive types of infections (iGAS). Incidence of iGAS is highest among the elderly, but the largest relative increase from previous seasons was seen among children. The study is being presented to the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, ...

Strep A infections among children surged in France across 2022, after nearly two-years of COVID-related low case numbers

2023-04-16
**Note: the release below is from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April). Please credit the conference if you use this story** New research from France shows that infections cause by Group A Streptococcus (GAS) fell by 80% as the first COVID lockdown took effect in March 2020 and stayed at low levels until March 2022, from which point they increased by 18% a month to rise well above pre-COVID levels. The study is being presented at the European Congress of Clinical Microbiology & Infectious Diseases in Copenhagen, Denmark (15-18 ...

LAST 30 PRESS RELEASES:

Lighting the way: how activated gold reveals drug movement in the body

SwRI-led PUNCH constellation launches

Cells “speed date” to find their neighbors when forming tissues

Food insecurity today, heart disease tomorrow?

Food insecurity and incident cardiovascular disease among Black and White US individuals

Association of diet and waist-to-hip ratio with brain connectivity and memory in aging

Evolution and current challenges of gastrointestinal endoscopy in Nigeria: insights from a nationwide survey

Transgender and gender diverse people less likely to receive follow-up after a mental health hospitalization

Long-lived families show lower risk for peripheral artery disease

Food systems, climate change, and air pollution: Unveiling the interactions and solutions

Tissue engineering offers new hope for spinal cord injury repair

Preclinical study finds earlier ACL reconstruction is associated with lower risk of knee osteoarthritis

Assessing pain, anxiety and other symptoms of nursing home residents unable to speak for themselves

Thirty-three centers join new Bronchiectasis and NTM Care Center Network

Effects of ethanol on the digestive system

KIER unveils blueprint for cost-effective production of eco-friendly green hydrogen

Blind to the burn: Misconceptions about skin cancer risk in the US

Young Australians demand action on mental health, cost of living and education reform: report

First national perception survey of Food is Medicine programs shows strong public support

UNCG professor investigates how symbiotic groups can behave like single organisms with $600,000 in Templeton Foundation funding

Targeted alpha therapy: a breakthrough in treating refractory skin cancer

Transforming thymic carcinoma treatment with a dual approach

Wrong on skin cares: keratinocytes, not fibroblasts, make collagen for healthy skin

Delhi air pollution worse than expected as water vapour skews figures

First radio pulses traced to dead-star binary

New membrane discovery makes possible cleaner lithium extraction

Entwined dwarf stars reveal their location thanks to repeated radio bursts

Landscape scale pesticide pollution detected in the Upper Rhine region, from agricultural lowlands to remote areas

Decoding nanomaterial phase transitions with tiny drums

Two-star system explains unusual astrophysical phenomenon

[Press-News.org] AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers
Phase I data represent first clinical proof-of-concept for targeting Hippo-YAP-TEAD pathway